Morgan Stanley Comments on Edwards Lifesciences

Morgan Stanley commented on Edwards Lifesciences EW. In a research report published today, Morgan Stanley stressed that a number of research had worrying implications for transapical implants. In the report, Morgan Stanley states, "While neither the analyses presented today at PCR nor the stroke data at AATS on May 9 indicate a link from transapical implants to adverse outcomes, physician concerns on the topic seem to be increasing. These signals are not present in the transfemoral data. Given that transapical implants account for roughly half the Sapien volume in Europe, this bears watching." At the moment, Morgan Stanley has an Equal-weight rating on Edwards. On Tuesday, Edwards lost 0.92% of its value to close the day at $88.47.